Discontinuation of non-anti-TNF drugs for rheumatoid arthritis in interventional versus observational studies: a systematic review and meta-analysisAlthough randomized controlled trials (RCTs) are the gold standard for the assessment of clinical outcomes, long-term extension trials (LTEs) and ...
that one cytokine, tumour-necrosis factor (TNF; previously known as TNF-α), has an important role in the pathogenesis of rheumatoid arthritis. This discovery heralded a new era of targeted and highly effective therapeutics for rheumatoid arthritis and, subsequently, other chronic inflammatory ...
Currently, five anti-TNF biologic agents are approved for the treatment of rheumatoid arthritis (RA): adalimumab, infliximab, etanercept, golimumab and certolizumab pegol. Formation of anti-drug antibodies (ADA) has been associated with all five agents. In the case of adalimumab and infliximab, imm...
heumatoid Arthritis Anti-TNF and Physiologic Measures of Metabolic Disease in Rheumatoid ArthritisAnti-TNF and Physiologic Measures of Metabolic Disease in Rheumatoid Arthritisdoi:10.1097/RHU.0000000000000920Lisa J. HerrintonG. Thomas RayJashin J. Wu...
Anti-TNF伪 in rheumatoid arthritisSchreiber, SSternon, J
Objectives: Tumor necrosis factor (TNF) is known to increase the concentrations of IL-6 and CRP and to induce pro-atherogenic changes in the lipid profile and could increase the cardiovascular risk of patients with rheumatoid arthritis (RA) and other inflammatorydisorders. The aim of this study ...
Tuberculous necrotizing fasciitis (NF) is an exceedingly rare condition, particularly in patients undergoing immunosuppressive therapy for autoimmune diseases such as rheumatoid arthritis. This case describes a 69-year-old male with a history of rheumatoid arthritis treated with...
When should treatment with tumor necrosis factor (TNF) blockers in a patient withrheumatoid arthritis(RA) be initiated? Samar, MD, FACP, FACR Response from the Expert Disease-modifying medications should be started as soon as the diagnosis of RA has been made. Therapeutic options range from non...
Anti-tumour necrosis factor-α (TNFα) antagonists are potent anti-inflammatory drugs widely used in patients with RA. Their ability to modulate cardiovascular risk has been evaluated in cohort studies, some of which indicated significant risk reduction in patients with established RA.10 11 A ...
The Journal of Clinical Fully Human Anti-TNF-伪 in Subjects With Rheumatoid ArthritisZhou, HonghuiJang, HaishanFleischmann, Roy MBoumanThio, EstherXu, ZhenhuaMarini, Joseph CJiao, QunShankar, GopiMarciniak, Stanley JCohen, Stanley B